📝 JHS Svendgaard Laboratories Limited — results explained
Quarter ended June 2026 (Q1 FY27)
JHS Svendgaard Laboratories Limited reported revenue of ₹30 crore for the quarter ended June 2026 (Q1 FY27), up 29.6% from ₹23 crore in the same quarter last year, and down 7.1% sequentially over the March 2026 quarter.
Net profit rose 3.0% year-on-year to ₹1 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹0.13.
Operating profit stood at ₹2 crore — an operating margin (OPM) of 6.8%, compared with 7.1% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, JHS Svendgaard Laboratories Limited posted revenue of ₹102 crore, a growth of 10.6% over FY25, with a net loss of ₹2 crore.
On a trailing-twelve-month (TTM) basis, revenue stands at ₹109 crore with a net loss of ₹2 crore.
Valuation snapshot
At the current price of ₹9.02, JHS has a market capitalisation of ₹79 crore.
Within the Personal Care - Indian industry, it is the 4th-largest of the 4 companies we track by market value.
Shareholding pattern
As of Sep 2026, promoters held 33.85%, foreign institutional investors (FIIs) 2.87%, public shareholders 63.28% of JHS Svendgaard Laboratories Limited.